Share price · ABBV
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ABBV's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 2 Nov 2026-2.1%
- 22 Jun 2026+6.2%
- 29 Apr 2026+3.1%
- 18 Mar 2026-5.2%
Nothing announced by ABBV that day or the session before.
- 12 Feb 2026+3.0%
Nothing announced by ABBV that day or the session before.
- 4 Feb 2026-3.8%
- 8 Jan 2026-4.0%
- 7 Jan 2026+4.2%
- 5 Jan 2026-4.0%
- 24 Nov 2025-2.9%
Share of unusual movement by asset
For each asset, the share of ABBV's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(78 total)
| Target & Modality | |||
|---|---|---|---|
adalimumab(Humira) | Approved | TNF-alphaMonoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid ArthritisHidradenitis SuppurativaNon-Infectious Uveitis Ulcerative Colitis, Crohn's Disease |
| Approved | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | SchizophreniaBipolar Disorder | |
| Approved | CGRP receptorSmall molecule | Migraine | |
| Approved | Dopamine D3/D2 receptor (partial agonist)Small molecule | Major Depressive DisorderSchizophreniaBipolar DisorderBipolar Depression | |
| Approved | GABAergic neurotransmissionSmall molecule | EpilepsyMigraineBipolar Disorder Focal Onset Seizures, Absence Seizures | |
| Approved | GABAergic neurotransmissionSmall molecule | EpilepsyMigraineBipolar Disorder Focal Onset Seizures, Absence Seizures | |
| Approved | SLAMF7 (CS1/CD319)Monoclonal antibody | Multiple Myeloma | |
| Approved | CD20 x CD3Multispecific antibody | Diffuse Large B-Cell LymphomaFollicular LymphomaNon-Hodgkin Lymphoma Large B-Cell Lymphoma, High-Grade B-Cell Lymphoma | |
foslevodopa/foscarbidopa(Vyalev) | Approved | dopamine precursorSmall molecule | Parkinson's Disease |
| Approved | BTKSmall molecule | Diffuse Large B-Cell LymphomaGraft-versus-Host DiseaseMantle Cell LymphomaChronic Lymphocytic Leukemia Chronic Graft-versus-Host Disease | |
| Approved | dopamine precursorSmall molecule | Parkinson's Disease | |
linaclotide(Linzess) | Approved | Guanylate cyclase-C (GC-C)Peptide | Irritable Bowel Syndrome Irritable Bowel Syndrome with Constipation |
| Approved | AminosalicylateSmall molecule | Inflammatory Bowel Disease Ulcerative Colitis | |
Mirvetuximab soravtansine(Elahere) | Approved | —Antibody–drug conjugate | Ovarian Cancer |
onabotulinumtoxinA(Botox) | Approved | Acetylcholine Release Inhibitor · acetylcholine releaseBiologic (subtype unspecified) | Migraine |
Discontinued programmes (6)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(130 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (12)
November 2026 (7)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
December 2026 (5)
What to watch
What to watch
What to watch
What to watch
2027 (39)
January 2027 (2)
February 2027 (4)
March 2027 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
April 2027 (1)
What to watch
May 2027 (3)
June 2027 (2)
July 2027 (2)
August 2027 (3)
What to watch
What to watch
What to watch
September 2027 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
October 2027 (1)
What to watch
November 2027 (4)
December 2027 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
2028 (25)
January 2028 (2)
February 2028 (4)
March 2028 (6)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
April 2028 (1)
What to watch
June 2028 (1)
What to watch
July 2028 (3)
August 2028 (3)
September 2028 (2)
2029 (19)
January 2029 (2)
What to watch
What to watch
February 2029 (3)
April 2029 (3)
May 2029 (1)
What to watch
June 2029 (1)
What to watch
July 2029 (1)
August 2029 (1)
What to watch
October 2029 (2)
November 2029 (2)
2030 (12)
January 2030 (1)
What to watch
February 2030 (1)
What to watch
March 2030 (1)
What to watch
April 2030 (2)
What to watch
September 2030 (2)
What to watch
October 2030 (2)
What to watch
What to watch
2031 (9)
January 2031 (1)
What to watch
March 2031 (1)
What to watch
April 2031 (1)
May 2031 (1)
What to watch
June 2031 (1)
What to watch
August 2031 (1)
2032 (5)
March 2032 (1)
What to watch
April 2032 (1)
What to watch
June 2032 (1)
What to watch
August 2032 (1)
What to watch
November 2032 (1)
What to watch
2033 (2)
February 2033 (1)
March 2033 (1)
What to watch
2034 (2)
July 2034 (1)
What to watch
2035 (2)
2036 (1)
November 2036 (1)
What to watch
2037 (1)
November 2037 (1)
What to watch
Regulatory and conference events
(39)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
The 12 most recent of 39 past events are shown.
Financial reports
Quarterly & interim (21)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $17.4B | $2.6B | $10.8B | —$7.6B operating cash flow | report ↗ |
View 20 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $17.0B | $2.3B | $6.6B | —$3.4B operating cash flow | report ↗ |
| 2026-Q1 | $15.0B | $2.5B | $9.4B | —$3.8B operating cash flow | report ↗ |
| 2025-Q4 | $16.6B | $2.6B | $5.3B+ $28M short-term inv. | —$5.2B operating cash flow | report ↗ |
| 2025-Q3 | $15.8B | $2.3B | $5.7B+ $42M short-term inv. | —$7.0B operating cash flow | report ↗ |
| 2025-Q2 | $15.4B | $2.1B | $6.5B+ $0 short-term inv. | —$5.2B operating cash flow | report ↗ |
| 2025-Q1 | $13.3B | $2.1B | $5.2B+ $1.0M short-term inv. | —$1.6B operating cash flow | report ↗ |
| 2024-Q4 | $15.1B | $6.8B | $5.6B+ $31M short-term inv. | —$7.0B operating cash flow | report ↗ |
| 2024-Q3 | $14.5B | $2.1B | $7.3B+ $28M short-term inv. | —$5.4B operating cash flow | report ↗ |
| 2024-Q2 | $14.5B | $1.9B | $13.2B+ $27M short-term inv. | —$2.3B operating cash flow | report ↗ |
| 2024-Q1 | $12.3B | $1.9B | $18.1B+ $2.0M short-term inv. | —$4.0B operating cash flow | report ↗ |
| 2023-Q4 | $14.3B | — | $12.8B+ $2.0M short-term inv. | —$4.8B operating cash flow | report ↗ |
| 2023-Q3 | $13.9B | $1.7B | $13.3B+ $3.0M short-term inv. | —$7.6B operating cash flow | report ↗ |
| 2023-Q2 | $13.9B | $1.7B | $8.8B+ $7.0M short-term inv. | —$6.3B operating cash flow | report ↗ |
| 2023-Q1 | $12.2B | $2.3B | $6.7B+ $11M short-term inv. | —$4.2B operating cash flow | report ↗ |
| 2022-Q4 | $15.1B | — | $9.2B+ $28M short-term inv. | —$7.4B operating cash flow | report ↗ |
| 2022-Q3 | $14.8B | $1.6B | $11.8B+ $47M short-term inv. | —$7.6B operating cash flow | report ↗ |
| 2022-Q2 | $14.6B | $1.6B | $8.5B+ $1.4B short-term inv. | —$5.0B operating cash flow | report ↗ |
| 2022-Q1 | $13.5B | $1.5B | $6.1B+ $1.5B short-term inv. | —$4.9B operating cash flow | report ↗ |
| 2021-Q4 | $14.9B | — | $9.7B+ $84M short-term inv. | —$5.1B operating cash flow | report ↗ |
| 2021-Q3 | $14.3B | $1.7B | $12.2B+ $67M short-term inv. | —$7.9B operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $61.2B | $9.1B | $5.3B+ $28M short-term inv. | —$19.0B operating cash flow | report ↗ |
AbbVie reported FY2025 revenue of $61,160M, up 305.0% YoY. R&D spend was $9,096M, up 34.3% YoY. Cash and equivalents stood at $5,257M, and the company recorded net income of $4,226M.
The company outlined 2026 strategic objectives including advancing late-stage pipeline milestones and expecting several regulatory submissions, approvals, and clinical data readouts over the next 12 months. Key developments included Rinvoq approvals for giant cell arteritis and positive Phase 3 results in alopecia areata and vitiligo, accelerated FDA approval of Emrelis, FDA approval of Epkinly for relapsed/refractory follicular lymphoma, and regulatory submissions for tavapadon, PVEK, and TrenibotE. The Venclexta VERONA trial missed its primary endpoint. AbbVie also announced a voluntary U.S. government agreement pledging $100 billion in U.S. R&D and capital investment, a CEO/board chairman transition effective July 2025, and Rinvoq patent settlements expected to prevent generic entry before April 2037.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $56.3B | $12.8B | $5.6B+ $31M short-term inv. | —$18.8B operating cash flow | report ↗ |
| 2023-FY | $54.3B | $7.7B | $12.8B+ $2.0M short-term inv. | —$22.8B operating cash flow | report ↗ |
| 2022-FY | $58.1B | $6.5B | $9.2B+ $28M short-term inv. | —$24.9B operating cash flow | report ↗ |
| 2021-FY | $56.2B | $7.1B | $9.7B+ $84M short-term inv. | —$22.8B operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 7 sales ($30.8M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-16 | SALEKI AZITA · EVP, CHIEF OPERATIONS OFFICER | Option exercise | 23,935 | $61.36 | $1.5M | Form 4 |
| 2026-11-16 | SALEKI AZITA · EVP, CHIEF OPERATIONS OFFICER | Tax withholding | 13,481 | $298.55 | $4.0M | Form 4 |
| 2026-11-16 | SALEKI AZITA · EVP, CHIEF OPERATIONS OFFICER | Option exercise (derivative) | 13,481 | — | — | Form 4 |
| 2026-11-12 | Stewart Jeffrey Ryan · EVP, CHIEF COMMERCIAL OFFICER | Gift | 3,450 | — | — | Form 4 |
| 2026-11-09 | Stewart Jeffrey Ryan · EVP, CHIEF COMMERCIAL OFFICER | Option exercise | 16,070 | $114.36 | $1.8M | Form 4 |
| 2026-11-09 | Stewart Jeffrey Ryan · EVP, CHIEF COMMERCIAL OFFICER | Option exercise | 24,549 | $93.50 | $2.3M | Form 4 |
| 2026-11-09 | Stewart Jeffrey Ryan · EVP, CHIEF COMMERCIAL OFFICER | Open-market sale | 40,619 | $293.60 | $11.9M | Form 4 |
| 2026-11-09 | Stewart Jeffrey Ryan · EVP, CHIEF COMMERCIAL OFFICER | Option exercise (derivative) | 16,070 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 3,998 reporting institutions held 1294.7M shares ($271.3B, 73.2% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 150,698,125 | $32.8B |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 114,880,324 | $25.0B |
| 3 | STATE STREET CORP | 81,217,516 | $17.7B |
| 4 | JPMORGAN CHASE & CO | 56,741,691 | $12.1B |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 49,523,078 | $10.8B |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 46,737,581 | $10.1B |
| 7 | MORGAN STANLEY | 38,016,774 | $8.3B |
| 8 | Capital Research Global Investors | 31,254,786 | $6.8B |
| 9 | BANK OF AMERICA CORP /DE/ | 23,936,943 | $5.2B |
| 10 | FMR LLC | 21,762,703 | $4.7B |
| 11 | NORTHERN TRUST CORP | 21,211,382 | $4.6B |
| 12 | Capital World Investors | 15,841,367 | $3.4B |
| 13 | GOLDMAN SACHS GROUP INC | 15,145,279 | $3.3B |
| 14 | FRANKLIN RESOURCES INC | 14,552,069 | $3.2B |
| 15 | Capital International Investors | 14,418,993 | $3.1B |